ALMS Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Alumis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.04 |
| 52 Week High | US$13.53 |
| 52 Week Low | US$7.66 |
| Beta | 0 |
| 1 Month Change | -15.01% |
| 3 Month Change | -30.15% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.55% |
Recent News & Updates
Alumis: A Best-In-Class TYK2 Inhibitor
Nov 28Alumis: Could This Broken Immunology IPO Become The Next Amgen?
Oct 04Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Sep 16Shareholder Returns
| ALMS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.0% | 1.6% | -2.2% |
| 1Y | n/a | 9.7% | 23.9% |
Return vs Industry: Insufficient data to determine how ALMS performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ALMS performed against the US Market.
Price Volatility
| ALMS volatility | |
|---|---|
| ALMS Average Weekly Movement | 11.3% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALMS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 146 | Matt Babler | www.alumis.com |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
Alumis Inc. Fundamentals Summary
| ALMS fundamental statistics | |
|---|---|
| Market cap | US$437.43m |
| Earnings (TTM) | -US$238.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs ALMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$238.77m |
| Earnings | -US$238.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:50 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alumis Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Yatin Suneja | Guggenheim Securities, LLC |